State Street’s Cytosorbents Corp CTSO Stock Holding History

State Street’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$90.2K	Hold	159,293	–	–	﹤0.01%	4044
2025 Q4	$102K	Hold	159,293	–	–	﹤0.01%	4042
2025 Q3	$149K	Hold	159,293	–	–	﹤0.01%	3978
2025 Q2	$204K	Hold	159,293	–	–	﹤0.01%	3830
2025 Q1	$159K	Hold	159,293	–	–	﹤0.01%	3875
2024 Q4	$145K	Buy	159,293 +19,000	+14%	+$18.6K	﹤0.01%	3917
2024 Q3	$210K	Hold	140,293	–	–	﹤0.01%	3815
2024 Q2	$98.6K	Hold	140,293	–	–	﹤0.01%	4019
2024 Q1	$133K	Sell	140,293 -10,800	-7%	-$10.5K	﹤0.01%	3971
2023 Q4	$168K	Hold	151,093	–	–	﹤0.01%	3937
2023 Q3	$284K	Hold	151,093	–	–	﹤0.01%	3834
2023 Q2	$542K	Sell	151,093 -900	-0.6%	-$2.85K	﹤0.01%	3669
2023 Q1	$512K	Hold	151,993	–	–	﹤0.01%	3738
2022 Q4	$236K	Sell	151,993 -5,600	-4%	-$8.31K	﹤0.01%	4041
2022 Q3	$214K	Hold	157,593	–	–	﹤0.01%	4115
2022 Q2	$345K	Sell	157,593 -565,096	-78%	-$1.3M	﹤0.01%	3980
2022 Q1	$2.31M	Buy	722,689 +1,901	+0.3%	+$6.81K	﹤0.01%	3505
2021 Q4	$3.02M	Sell	720,788 -1,179	-0.2%	-$6.62K	﹤0.01%	3488
2021 Q3	$5.86M	Buy	721,967 +7,557	+1%	+$61.4K	﹤0.01%	3146
2021 Q2	$5.39M	Buy	714,410 +56,624	+9%	+$477K	﹤0.01%	3208
2021 Q1	$5.71M	Buy	657,786 +13,376	+2%	+$127K	﹤0.01%	2997
2020 Q4	$5.14M	Buy	644,410 +31,180	+5%	+$261K	﹤0.01%	2941
2020 Q3	$4.89M	Buy	613,230 +53,618	+10%	+$484K	﹤0.01%	2804
2020 Q2	$5.54M	Buy	559,612 +20,530	+4%	+$189K	﹤0.01%	2711
2020 Q1	$4.17M	Sell	539,082 -12,994	-2%	-$65.6K	﹤0.01%	2721
2019 Q4	$2.13M	Buy	552,076 +41,540	+8%	+$181K	﹤0.01%	3221
2019 Q3	$2.57M	Sell	510,536 -11,902	-2%	-$69.2K	﹤0.01%	3126
2019 Q2	$3.45M	Buy	522,438 +39,691	+8%	+$273K	﹤0.01%	3014
2019 Q1	$3.65M	Buy	482,747 +12,552	+3%	+$97.7K	﹤0.01%	2904
2018 Q4	$3.8M	Sell	470,195 -132	-0%	-$1.31K	﹤0.01%	2849
2018 Q3	$6.07M	Buy	470,327 +35,695	+8%	+$448K	﹤0.01%	2766
2018 Q2	$4.96M	Buy	434,632 +413,053	+1,914%	+$3.91M	﹤0.01%	2856
2018 Q1	$153K	Buy	21,579 +2,874	+15%	+$21.7K	﹤0.01%	3582
2017 Q4	$122K	Buy	18,705 +6,705	+56%	+$42.7K	﹤0.01%	3594
2017 Q3	$74K	Hold	12,000	–	–	﹤0.01%	3649
2017 Q2	$51K	Hold	12,000	–	–	﹤0.01%	3592
2017 Q1	$54K	Hold	12,000	–	–	﹤0.01%	3571
2016 Q4	$65K	Hold	12,000	–	–	﹤0.01%	3546
2016 Q3	$77K	Hold	12,000	–	–	﹤0.01%	3462
2016 Q2	$55K	Hold	12,000	–	–	﹤0.01%	3583
2016 Q1	$47K	Hold	12,000	–	–	﹤0.01%	3620
2015 Q4	$67K	Hold	12,000	–	–	﹤0.01%	3576
2015 Q3	$75K	Hold	12,000	–	–	﹤0.01%	3556
2015 Q2	$73K	Hold	12,000	–	–	﹤0.01%	3560
2015 Q1	$158K	Buy	+12,000	New	+$123K	﹤0.01%	3510

Other funds holding CTSO

Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street's CTSO Position: Q1 2026 in Review

State Street held its Cytosorbents Corp (CTSO) position steady in Q1 2026 at 159,293 shares worth $90.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4044.

State Street first reported a position in CTSO in Q1 2015 and has held it in 45 quarters since. The position peaked at $6.07M in Q3 2018. 50 funds tracked by Wall St. Rank hold CTSO as of Q1 2026.

State Street held 159,293 shares of Cytosorbents Corp worth $90.2K as of Q1 2026.
State Street left its Cytosorbents Corp share count unchanged in Q1 2026.
Cytosorbents Corp made up ﹤0.01% of State Street's portfolio in Q1 2026, its #4044 holding.
State Street first reported a position in Cytosorbents Corp in Q1 2015 and has held it in 45 quarters since.
State Street's Cytosorbents Corp position peaked at $6.07M in Q3 2018.
50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.